I
n the United States, cardiovascular disease accounts for nearly 40% of all deaths each year (1) . The factors that make up the Framingham risk score (age, sex, blood pressure, serum total cholesterol or low-density lipoprotein cholesterol level, high-density lipoprotein cholesterol level, cigarette smoking, and diabetes) account for most of the excess risk for incident coronary heart disease (CHD) (2, 3) . However, these factors do not explain all of the excess risk (4, 5) , and approximately 40% of CHD deaths occur in persons with cholesterol levels that are lower than the population average (6) . Several lines of evidence (7, 8) have implicated chronic inflammation in CHD, and inflammatory markers have received much attention as new or emerging risk factors that could account for some of the unexplained variability in CHD risk.
C-reactive protein (CRP) is a sensitive, nonspecific systemic marker of inflammation (9) . Although it is unknown whether CRP is involved in CHD pathogenesis (10, 11) , elevated serum CRP levels are associated with traditional cardiovascular risk factors and obesity (12, 13) . In 2002, an expert panel recommended against routine use of CRP in risk assessment for primary prevention of CHD but supported CRP measurement in persons with a 10-year CHD risk of 10% to 20%. It noted that the benefits of this strategy "remain uncertain" and recommended further research into the implications of using CRP in risk categorization for therapeutic risk reduction in patients (14) .
The potential clinical benefit of new risk factors for refining global risk assessment is thought to be greatest for persons who are classified as intermediate-risk when stratified by using conventional risk factors (15) . In the Framingham risk scoring system, intermediate-risk persons are those with a 10% to 20% risk for coronary death or nonfatal myocardial infarction ("hard CHD events") over 10 years. Further stratification by using new markers might reclassify some intermediate-risk persons as low-risk (10-year risk Ͻ10%) and others as high-risk (10-year risk Ͼ20%). This would permit more aggressive risk reduction therapy in persons reclassified as high-risk and may consequently reduce incident CHD events (16) .
Several previous meta-analyses (17) (18) (19) have assessed the possible independent predictive ability of CRP level for incident CHD risk. In 1998, a meta-analysis of 5 longterm, population-based prospective cohort studies and 2 cohorts of patients with preexisting CHD (17) calculated a risk ratio for coronary events of 1.7 (95% CI, 1.4 to 2.1) for CRP levels in the top tertile versus the bottom tertile. An update of this meta-analysis in 2000 (18) included 7 additional studies. The combined risk ratio for the 11 population-based prospective cohort studies of persons without preexisting CHD was 2.0 (CI, 1.6 to 2.5). Another update in 2004 (19) included 11 new studies as well as the 11 previous cohorts. The combined odds ratio for all 22 studies was 1.58 (CI, 1.48 to 1.69).
These 3 meta-analyses, however, lacked a systematic assessment of the characteristics and quality of study design and execution. In particular, they did not systematically assess the degree of adjustment for standard measures of CHD risk (such as the Framingham risk score). Although the first 2 meta-analyses reported the degree of adjustment for potential confounders in each of the included studies, they did not specify how many or which standard coronary risk factors were adjusted for. Furthermore, these metaanalyses did not use the degree of adjustment as a basis for quality rating or inclusion. The most recent meta-analysis (19) did not rate quality or degree of adjustment for potential confounders. In addition, because the investigators used broad inclusion criteria, the studies in these metaanalyses do not necessarily represent the intermediate-risk population.
We conducted a systematic review and meta-analyses of epidemiologic studies to help the U.S. Preventive Services Task Force (USPSTF) determine whether CRP level should be incorporated into guidelines for coronary and cardiovascular risk assessment in primary care. Our review addresses the question of whether elevated CRP levels are independently predictive of incident CHD events, specifically among intermediate-risk persons. Our approach incorporated elements previously used by the USPSTF (20) and several domains of the approach developed by the Grading of Recommendations, Assessment, Development, and Evaluation workgroup (21) .
METHODS

Data Sources and Searches
We searched MEDLINE for original epidemiologic studies published between 1966 and November 2007. Our search strategy included the terms cardiovascular diseases, C-reactive protein, inflammation, and biological markers and was limited to articles published in English. We obtained additional articles from recent systematic reviews; reference lists of pertinent studies, reviews, editorials, and Web sites; and consultations with experts.
Study Selection
We included studies that published original data relevant to measuring the increased risk for incident CHD associated with elevated CRP level. We only considered prospective cohort studies (including those based on a cohort within a randomized trial), case-cohort studies, and nested case-control studies. We only included studies that had a follow-up of 2 years or more, reported the outcomes of coronary death and nonfatal myocardial infarction, and adjusted for a minimum of 5 of the 7 risk factors used in the Framingham risk score. We excluded studies in which no participants were likely to be classified as intermediaterisk by using the Framingham risk score and those conducted exclusively in patients with previously diagnosed coronary disease, coronary disease equivalents (such as diabetes), or medical conditions that may cause premature CHD. We included studies in which some patients had cardiovascular disease at baseline only if the studies adjusted for prevalent disease in their analysis. The full systematic evidence report (22) provides a more detailed description of our study methods.
Data Extraction and Quality Assessment
One investigator reviewed the relevant articles and recorded overlap with the studies included in previous metaanalyses. For our meta-analyses, when multiple articles were published from a single cohort, we included the findings from the analysis with the highest applicability to the study question and the highest validity, on the basis of our quality ratings. In general, we selected cohort studies over nested case-control studies, good-quality studies over fairquality studies, studies that adjusted for more Framingham risk variables, studies with longer follow-up, and studies that most closely addressed our principal question.
We used standardized forms to abstract data on study design, population, size, CRP measurement, Framingham risk factor measurement, length of follow-up, outcomes, and data analysis. For each study, we recorded how many Framingham risk factors and other confounding factors were included in the model; whether the investigators reported model fit measures, discrimination measures, or model calibration statistics separately for models with and without CRP; and whether the study assessed the degree to which persons were reclassified on the basis of CRP level, overall or in the intermediate-risk group.
Two investigators used the USPSTF criteria (20) to independently assess the quality of each study as good, fair, or poor. These criteria are specific to the study design (cohort or nested case-control) and include such items as appropriate assembly or ascertainment of the cohort or the case patients and control participants, reliability and equal application of measurements, response or follow-up rate, and appropriate adjustment for confounding. Because we sought to evaluate the predictive ability of CRP independent of the Framingham risk factors, we required that a study adjust for all 7 of the Framingham variables to reClinical Guidelines CRP as a Risk Factor for CHD ceive a quality rating of "good," even if the study otherwise had high internal validity. We resolved disagreements regarding quality by discussion, further review, and adjudication by a third reviewer (if necessary).
Data Synthesis and Analysis
The ideal approach to assessing the clinical effect of expanding the Framingham risk score has been debated extensively. Most previous research on the effect of a new risk factor has focused on the c-statistic, a measure of discrimination. The c-statistic, however, may be a poor indicator of the effect of using CRP level to further stratify persons classified as intermediate-risk by the Framingham risk score. For this reason, recent literature (23) (24) (25) (26) has emphasized that studies should examine how well assessing CRP level improves risk prediction and further risk stratification among persons initially classified as intermediate-risk.
Most studies provided an overall estimate of the risk associated with high CRP levels, after adjustment for other risk factors, but did not provide specific evidence about the intermediate-risk group. For these studies, we conducted 2 meta-analyses to obtain pooled adjusted risk ratios for the association of hard CHD events and CRP level. The first included all studies that were fair-quality or better, adjusted for at least 5 Framingham risk factors, included at least some participants who were likely to be at intermediate risk, and estimated the risk for CHD associated with CRP level after adjusting for confounders. Because including studies that had methodological flaws or assessed fewer Framingham risk factors could have led to overestimation of the pooled risk ratio, we conducted a second metaanalysis that was restricted to good-quality studies, all of which adjusted for all Framingham risk factors.
Because different studies reported ratios for different cutoff levels (including tertiles, quartiles, or quintiles), or as an increase in risk for a given unit of increase in CRP level, we standardized the risk ratio of CRP level for our metaanalyses to provide clinically relevant and easily interpretable results. We used currently recommended cutoff points (14) for low (Ͻ1.0 mg/L), average (1.0 to 3.0 mg/L), and high (Ͼ3.0 mg/L), with less than 1.0 mg/L as a reference. When studies used other cutoff points to categorize CRP level, we calculated risk ratios at cutoff points of 1.0 and 3.0 mg/L by assuming a log-normal distribution of CRP level (17, 27 ) and a log-linear association of CHD risk over the midrange of log-CRP levels (17, 28) . We estimated distribution parameters of CRP level from published information from each study. We estimated CIs by using reported SEs for the coefficient of CRP level when studies analyzed CRP level as a continuous variable and by applying the same assumption of a log-linear relationship when studies categorized CRP level by using other cutoff points. We combined the risk ratio estimates by using a randomeffects model to incorporate variation among studies into the combined estimate (29) . We assessed statistical heterogeneity among the studies by using standard chi-square tests and estimated the magnitude of heterogeneity by using the I 2 statistic (30). We used random-effect metaregression to examine possible sources of heterogeneity and investigate whether the risk ratio estimates were associated with various study-level characteristics (30) . We tested whether the distribution of the effect sizes was symmetric with respect to the precision measure by using funnel plots and the Egger linear regression method (31) . We used Stata, version 10.0 (StataCorp, College Station, Texas), to perform the analyses.
Although our meta-analyses addressed whether CRP adds information to the Framingham risk score, they could not assess how well risk ratios derived from the entire population apply to intermediate-risk participants, or how those participants would be reclassified if CRP were used. To examine reclassification, we identified and critically appraised the studies that either compared predictive models that used all Framingham risk factors, with and without CRP levels, or measured the incidence of CHD events among intermediate-risk participants classified by CRP levels.
Role of the Funding Source
The Agency for Healthcare Research and Quality suggested the topic and provided copyright release for this manuscript but did not participate in the literature search, data analysis, or interpretation of the results.
RESULTS
Study Characteristics
Of 1292 abstracts of potentially relevant studies, 37 published studies (8, 18, 19, 23, 28, Tables 1 and 2 , available at www.annals.org, have more information on these studies.) From these, we identified 23 principal articles that represented the most pertinent publication for meta-analysis from each of the 24 cohorts (18, 19, 28, 33, 35, 37, 42-46, 48, 50 -52, 54 -56, 59 -63) (Table) . All but 1 study (37) explicitly excluded patients with baseline CHD or cardiovascular disease, and this study adjusted for prevalent CHD. All studies measured CRP level by using a high-sensitivity CRP assay.
Thirteen of the 24 cohorts in our review were also included in the 2004 meta-analysis (19) . Five of these 13 cohorts were represented by the same article in both our meta-analysis and the previous meta-analysis (18, 19, 46, 48, 54) . For the other 8, we used more recent articles (33, 37, 42, 51, 52, 56, 59, 60) . We included 1 additional cohort study published in 2002 (28) and studies from 10 new cohorts published after the timeframe of the previous meta-analysis (35, 43-45, 50, 55, 61-63) . We excluded studies from 8 cohorts that the previous meta-analysis had included. Most of these were studies in which the participants were or were likely to be at increased risk for CHD (64 -69). We excluded 2 
Meta-analysis of Fair-Quality or Better Studies
Our meta-analysis of the 22 studies (in 23 cohorts) that explicitly excluded baseline CHD yielded a risk ratio of 1.60 (CI, 1.43 to 1.78) for high versus low CRP levels (Figure 1 ) and 1.26 (CI, 1.17 to 1.35) for average versus low CRP levels (Figure 2) . Including the study that did not explicitly exclude baseline CHD (37) did not appreciably change the combined risk ratio estimates. We found statistically significant heterogeneity of effects among studies at a P value less than 0.100, both for the comparison of high versus low CRP levels (I 2 ϭ 31.9%; P ϭ 0.072) and average versus low CRP levels (I 2 ϭ 44.0%; P ϭ 0.015). However, the standardized estimates of effect were consistently positive, with a range of 0.98 to 2.75 for high CRP levels and 0.99 to 1.88 for average CRP levels. Furthermore, the positive relationship persisted in analyses of all subgroups at both high and average levels of CRP ( Figure  3) . In subgroup meta-regression analyses, we found no statistically significant differences among categories for any study-level characteristic, including number of Framingham variables and other covariates adjusted, outcome measures (major CHD events vs. major CHD plus other CHD events or cardiovascular events), study design, sex, quality rating, and length of follow-up. We conducted a sensitivity analysis to compare the 17 studies that required standardization of risk ratios with the 6 studies that used recommended cutoffs. The combined risk ratio estimates were similar between the 2 groups of studies. We detected no statistically significant asymmetry when we examined funnel plots or used the Egger linear regression method and no evidence of a tendency for smaller studies to show a larger degree of association.
Meta-analysis of Good-Quality Studies
We also performed a meta-analysis limited to the 10 good-quality studies from 11 cohorts, all of which adjusted for all Framingham risk factors or calculated a Framingham risk score (33, 42, 44 -46, 52, 55, 56, 60, 61) . The relative risk was 1.58 (CI, 1.37 to 1.83) for high versus low CRP levels (Figure 1 ) and 1.22 (CI, 1.11 to 1.33) for average versus low CRP levels (Figure 2) . We found no statistically significant heterogeneity of effects among studies in this analysis. We excluded 4 fair-quality studies that used all Framingham risk factors (43, 50, 59, 62) . We conducted a sensitivity analysis and found similar results with and without these 4 studies. The relative risk was 1.53 (CI, 1.36 to 1.73) for high versus low CRP levels and 1.20 (CI, 1.12 to 1.29) for average versus low CRP levels.
Reclassification of Persons at Intermediate Risk
From a clinical perspective, the most meaningful measure of CRP's value as a marker is its effect on rates of reclassification from intermediate-risk to other risk categories. Recent articles (24 -26, 72) have proposed methods of assessing clinical risk reclassification when the goal of analysis is risk prediction. They note that measures of risk reclassification are probably better than the c-statistic for assessing the value of adding a new marker to a prediction model.
Five studies (23, 33, 40, 43, 56) included an analysis that compared predictive models that used all Framingham risk factors, with and without CRP level, specifically among participants whose 10 (33) , assessing CRP level in addition to the Framingham risk factors resulted in improved risk classification among participants with an initial 10-year risk of 11% to 19%. Among participants with a CRP level greater than 3.0 mg/L, some with an initial 10-year risk of 15% to 19% were reclassified as high-risk, whereas no participants with an initial 10-year risk of 11% to 14% were reclassified as high-risk. In an analysis of data from the Women's Health Study (40) , CRP level was clearly predictive of incident cardiovascular disease among participants with 10-year Framingham risk scores between 10% and 20%. The risk for cardiovascular events was twice as high for those with CRP levels between 1.0 and 3.0 mg/L or 83 (0.88-3.82)   1.75 (0.88-3.47)   1.72 (1.24-2.39)   2.21 (1.49-3.27)   1.53 (0.89-2.62)   1.79 (1.14-2.83)   1.45 (1.14-1.86 
DISCUSSION
The body of evidence that CRP level is independently associated with incident CHD is strong, with a risk ratio of 1.58 (CI, 1.37 to 1.83). Our search and systematic selection identified 23 studies of appropriate design from 24 cohorts. The aggregate quality of these studies is good to fair, and the body of evidence has no important inconsistency. We found no indication that the data from included studies were imprecise or sparse and no indication of high risk for reporting bias. We also noted some evidence of a dose-response gradient. These criteria support the conclusion of a strong body of evidence. Previous meta-analyses (17-19) have found an association between CRP level and incident CHD. These meta-analyses were limited by their lack of a systematic basis for judging the validity of the evidence they used, and applicability to the target population and question of interest may be limited. Our systematic review and CHD ϭ coronary heart disease; CRP ϭ C-reactive protein; CVD ϭ cardiovascular disease. * Number of cohorts included in the analysis. † Framingham risk factors are based on reference 2.
Clinical Guidelines CRP as a Risk Factor for CHD meta-analyses included more recent and updated studies, excluded studies of predominantly high-risk or lowrisk populations, systematically rated the quality of all studies, and qualitatively appraised findings that are directly applicable to intermediate-risk patients. The clinical implications of the association of CRP level with CHD events are less clear, because the pooled risk ratio does not necessarily measure the usefulness of CRP level in reclassifying intermediate-risk persons. The underlying studies did not directly assess whether the risk ratio for the overall sample applied to the intermediate-risk subgroup (for example, by looking for an interaction between the Framingham risk score and CRP levels). The strength of evidence from studies that attempted to measure the effect of using CRP level to improve risk classification among persons initially classified as intermediate-risk is moderate. Among intermediate-risk persons, subgroups with high CRP levels generally had a higher risk for coronary events than did those with average or low CRP levels.
In addition to multivariate regression analyses in prospective studies, many investigators (72) (73) (74) (75) have advocated the use of other statistical methods to assess the incremental value of adding CRP level to global risk assessment. Several studies in our review (23, 33, 40, 42, 43, 50, 56, 58) compared predictive models that used all Framingham risk factors with and without a CRP level. Most of these used the change in the c-statistic or the area under the receiver-operating characteristic curve to compare the performance after adding CRP level. However, a marker can have a small effect on the c-statistic, a measure of discrimination, but be strongly related to risk as assessed in a multiple logistic or Cox regression model, or vice versa (76 -78) . Recent articles (24 -26, 72) have discussed the limitations of the c-statistic and proposed methods of assessing clinical risk reclassification when risk prediction is the goal of analysis.
Relatively few studies have evaluated the effect of adding CRP level to reclassify initially intermediate-risk persons. Four studies in our review (33, 40, 43, 56 ) assessed differences in CHD risk among subgroups of intermediaterisk participants who were stratified by CRP level. Three of the 4 studies (33, 40, 56) found that those with higher CRP levels were at higher risk for CHD. However, their results are imprecise and their estimates are group averages, so they do not show how many persons would be reclassified as high-risk. A fifth study (23) calculated the risk reclassification when CRP level was added to a predictive model that included all Framingham risk score variables and found that the model with CRP level had better calibration to observed risk. In the negative study (43) , researchers of the Framingham cohort concluded that CRP level does not seem to be beneficial for CHD risk assessment, particularly because adding CRP level to the risk model did not improve c-statistic results. Recently, these researchers reported a good-quality analysis of Framingham data (79) in which they calculated the risk reclassification of individual study participants when CRP level was added to traditional risk factors; including CRP level improved risk assessment by appropriately reclassifying a statistically significant percentage of incident CHD cases and noncases into higher or lower risk categories.
Although the types of analyses differed, 4 large, goodquality cohort studies are consistent in finding that assessing CRP level improves CHD risk stratification (23, 33, 40, 56, 79) . These consistent findings provide moderately strong evidence that adding CRP level to risk models in intermediate-risk patients improves the identification of those at higher risk for incident CHD. However, additional research is needed to assess the effect of CRP level on risk reclassification of initially intermediate-risk persons and to statistically evaluate the calibration of prediction models to observed risk (26) .
Establishing the independent predictive ability of a new risk factor is necessary but not sufficient for assessing its potential usefulness in screening for CHD risk. Other criteria must be considered, such as the prevalence of the factor in the target population, the reliability and cost of the test, potential harms of testing, and the effect that treatment for the risk factor has on modifying risk (80). C-reactive protein level favorably satisfies most of these criteria. National survey data suggest a prevalence of high CRP level of at least 20% to 25% among intermediaterisk persons (13, 81) . Inexpensive, precise, high-sensitivity CRP serum assays are available (82, 83) . Although considerable within-patient variation among CRP measurements has been reported (84), the reliability of 2 or 3 serial measurements is similar to that of a total cholesterol assay (84, 85) . Weight loss, exercise, and smoking cessation can reduce serum CRP levels (86, 87) , and lowering CRP levels with statin therapy in patients with acute coronary syndrome can lower their risk for recurrent myocardial infarction or coronary death (88) . The viability of CRP as a new factor in global risk assessment for incident CHD is limited by sparse evidence that directly links therapeutic changes in CRP level to primary prevention of CHD events.
Results were recently published for JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), a good-quality randomized, controlled trial of rosuvastatin for primary prevention of cardiovascular events in 17 802 men and women with elevated (Ͼ2 mg/L) CRP levels, low-density lipoprotein cholesterol levels less than 3.4 mmol/L (Ͻ130 mg/dL) (median, 2.8 mmol/L [108 mg/dL]), and no other indication (such as diabetes) for statin therapy (89) . Of 8901 participants who received 20 mg of rosuvastatin daily, 83 experienced first cardiovascular events (myocardial infarction, stroke, or death from cardiovascular causes) during the study period (median, 1.9 years), compared with 157 of 8901 participants in the placebo group, for a hazard ratio of 0.53 (CI, 0.40 to 0.69). By 1 year of follow-up, the median low-density lipoprotein cholesterol level was un- To fully understand the balance of benefits and harms associated with any particular form of intensive risk reduction intended for patients classified according to CRP levels, we also need to know the numbers needed to treat and the harms for different risk category subgroups. The length of follow-up was inadequate to fully evaluate the potential harms of aggressive statin therapy (90) . When the trial was terminated, only 1076 (1 in 18) participants had 4 years of follow-up, and 2705 had 3 years of follow-up.
Other issues may influence guideline recommendations and merit discussion. Cross-sectional studies have found correlations between CRP level and traditional CHD risk factors (91) , but the implications for the use of CRP in global risk assessment are not clear. The findings have been interpreted to mean that CRP level may represent a different aspect of risk, with complex interrelationships among CRP level, traditional risk factors, and CHD (91, 92) . Others conclude that elevated CRP level is largely attributable to traditional risk factors, and CRP level "may have limited clinical utility as a screening tool" (13) . In fact, the causal relationships between CRP level and traditional CHD risk factors are not clear (93) . Correlation of CRP level with traditional risk factors does not preclude its potential association with CHD. The findings of many studies, including our meta-analyses, suggest that the degree of correlation between CRP level and traditional risk factors is not so great that CRP loses its independent effect. Although this statistical independence does not establish causality (94), it does support the potential use of CRP level as an adjunct in global risk assessment, particularly for targeted groups-such as intermediate-risk persons.
Our review has limitations. Studies used varying definitions, cutoffs, and methods of measurement for the Framingham risk factors and other cofactors. We accounted for these differences in our quality assessments and standardized our meta-analyses to recommended cut-off values. Because all studies were prospective, the likelihood of differential bias in measurement or reporting within studies is low. However, the net effect of the Framingham variables may vary from that of a calculated Framingham risk score for studies that did not measure each variable as defined for the Framingham risk score. In addition, although we distinguished those studies that completely adjusted for Framingham factors in our quality assessments and subgroup analyses, the inclusion of a nonuniform assortment of additional potential confounders might influence a study's relative risk estimate, with the net effect expected to be a reduction in the magnitude. Minority populations were poorly represented in most studies in our review. Ethnic and racial differences in biomarker levels (95, 96) and applicability of the Framingham risk score (97, 98) may limit the generalizability of our results.
In summary, our systematic review and meta-analyses indicate that CRP level is independently associated with incident CHD. The clinical implication of this finding is less clear, because the pooled risk ratio does not necessarily measure the usefulness of CRP level in reclassifying intermediate-risk persons. Although current evidence on the risk reclassification that would result from adding CRP level to a global risk score is promising, the strength of evidence from the 4 cohorts that attempted to measure the effect of using CRP among intermediate-risk persons is moderate. The viability of CRP as an adjunct to traditional factors is also uncertain because evidence linking changes in CRP level to primary prevention of CHD events is insufficient.
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